1. INTRODUCTION
===============

It is well established that cancer patients are at an increased risk of venous thromboembolism ([vte]{.smallcaps}). In fact, the presence of malignancy increases the risk of [vte]{.smallcaps} by a factor of 4 to 6, and large population-based studies show that the incidence of [vte]{.smallcaps} is on the rise [@b1-co15_s1p058],[@b2-co15_s1p058]. Overall, cancer patients constitute 15%--20% of the patients diagnosed with [vte]{.smallcaps}, and depending on the type of tumour, extent of malignancy, type of cancer treatment, and presence of other risk factors, 1%--25% of patients with malignancy will develop thrombosis.

Furthermore, cancer-associated thrombosis is linked with poor prognosis, and it is the second leading cause of death in cancer patients [@b3-co15_s1p058]. In one study of a population registry, the 1-year survival of cancer patients diagnosed with [vte]{.smallcaps} was one third that of cancer patients without [vte]{.smallcaps} (12% vs. 36%) matched for sex, age, tumour type, and duration of the cancer [@b4-co15_s1p058]. In another population-based study, the in-hospital mortality for cancer patients who developed [vte]{.smallcaps} while in hospital was double that for patients who did not develop the complication [@b5-co15_s1p058]. This increase in mortality is partly attributable to fatal pulmonary embolism, but it also reflects the advanced stages of cancer and underlying aggressive tumour biology in these patients.

Cancer patients are also prone to adverse effects and failure of anticoagulant therapy. In comparison with patients without cancer, patients with cancer who are receiving warfarin experience 2 to 6 times more major bleeding episodes and 2 to 3 times more [vte]{.smallcaps} recurrences [@b6-co15_s1p058],[@b7-co15_s1p058]. Based on prospective studies, the annual risk of recurrent [vte]{.smallcaps} is 21%--27% and the annual risk of major bleeding is 12%--13%.

Primary prevention is the most effective way to reduce the morbidity and mortality associated with cancer-associated thrombosis, but surveys and registries consistently report the failure of physicians to comply with established guidelines leading to underutilization of primary prophylaxis in oncology patients [@b8-co15_s1p058]. Given the impact that [vte]{.smallcaps} has on this high-risk population, an increased focus on identifying optimal methods to prevent and treat [vte]{.smallcaps} in patients with malignancy is needed. Current management strategies, and the evidence supporting them, are presented here.

2. PRIMARY PREVENTION: SURGICAL SETTINGS
========================================

The risk of [vte]{.smallcaps} in cancer patients undergoing surgery has been estimated to be as high as 50% without prophylaxis [@b9-co15_s1p058]. The exact risk varies with the type of surgery, but anticoagulants are generally effective in reducing the risk by 50%--80%. [Tables I](#tI-co15_s1p058){ref-type="table"} to [iii](#tIII-co15_s1p058){ref-type="table"} summarize the results from randomized controlled trials evaluating the efficacy and safety of anticoagulant prophylaxis in various oncologic surgery settings [@b10-co15_s1p058]--[@b23-co15_s1p058].

2.1 Major Abdominal and Pelvic Surgery
--------------------------------------

After major abdominal or pelvic cancer surgery, pharmacologic intervention with anticoagulants for 7--14 days postoperatively can reduce the risk of [vte]{.smallcaps} to 1.3% for symptomatic deep vein thrombosis ([dvt]{.smallcaps}) and 0.4% for fatal pulmonary embolism. However, these numbers still represent a doubling or tripling of the risk as compared with patients without malignancy [@b24-co15_s1p058],[@b25-co15_s1p058]. Of the agents available for thromboprophylaxis, low molecular weight heparins ([lmwh]{.smallcaps}s) provide the most convenient, efficacious, and safe option ([Table I](#tI-co15_s1p058){ref-type="table"}) [@b10-co15_s1p058]--[@b14-co15_s1p058],[@b26-co15_s1p058]. Compared with [lmwh]{.smallcaps}s, unfractionated heparin requires 3-times-daily injection and has a higher risk of heparin-induced thrombocytopenia. And although fondaparinux appears to be comparable to [lmwh]{.smallcaps} in efficacy and safety, limited data are available for it in the cancer setting, and a specific antidote for it is lacking. A *post hoc* subgroup analysis of cancer patients in a randomized trial found a lower risk of [vte]{.smallcaps} with fondaparinux than with dalteparin, but that finding requires confirmation in future studies [@b12-co15_s1p058].

However, as hospital stays have shortened, the duration of prophylaxis may be inadequate for some patients. Cancer patients are at particularly high risk, considering that many of them undergo extensive surgery and require prolonged periods of recovery. In a prospective cohort study in which 2373 cancer patients were followed for a minimum of 30 days after surgery, 40% of symptomatic VTE occurred more than 3 weeks postoperatively, and 46% of deaths were the result of fatal pulmonary embolism [@b27-co15_s1p058]. Clinical factors found to be associated with a higher risk of [vte]{.smallcaps} were previous history of [vte]{.smallcaps} \[odds ratio ([or]{.smallcaps}): 6.0\], anaesthesia lasting 2 hours or longer ([or]{.smallcaps}: 4.5), bed rest for 4 days or longer ([or]{.smallcaps}: 4.4), an advanced stage of cancer ([or]{.smallcaps}: 2.7), and age 60 years or older ([or]{.smallcaps}: 2.6).

Randomized controlled trials have shown that continuing prophylaxis with a [lmwh]{.smallcaps} up to 30 days postoperatively can reduce the risk of [vte]{.smallcaps} by 60% without increasing the risk of bleeding ([Table I](#tI-co15_s1p058){ref-type="table"}) [@b13-co15_s1p058],[@b14-co15_s1p058]. Based on these and other supportive studies, it is reasonable to prescribe extended prophylaxis in patients with one or more risk factors for [vte]{.smallcaps}.

2.2 Neurosurgery
----------------

Neurosurgical patients present a challenging prophylaxis problem because of the underlying concern of intracerebral hemorrhage combined with a high incidence of [vte]{.smallcaps}. In fact, craniotomy for brain neoplasm carries a [vte]{.smallcaps} risk of 60% in the postoperative period and 23% at 1 year [@b28-co15_s1p058]. This risk can be reduced by 40% with the use of [lmwh]{.smallcaps} prophylaxis starting 24 hours postoperatively ([Table II](#tII-co15_s1p058){ref-type="table"}) [@b15-co15_s1p058]--[@b18-co15_s1p058]. The risk of major bleeding, including intracranial hemorrhage, is less than 3%, but that risk is increased if [lmwh]{.smallcaps} prophylaxis is administered preoperatively [@b29-co15_s1p058]. However, given the devastating consequences of an intracranial hemorrhage, most neurosurgeons prefer to use mechanical compression devices in the early operative period and to start pharmacologic prophylaxis when patients are more stable.

2.4 Gynecologic Surgery
-----------------------

Compared with the previous two groups, women undergoing gynecologic cancer surgery have a lower risk of [vte]{.smallcaps}---about 2%. But that level of risk represents an increase by a factor of 5 over the risk in women having surgery for benign gynecologic problems [@b9-co15_s1p058]. As with abdominal and pelvic surgery, unfractionated heparin and [lmwh]{.smallcaps} are both equally effective and safe in preventing [dvt]{.smallcaps} in this setting ) ([Table III](#tIII-co15_s1p058){ref-type="table"} [@b19-co15_s1p058]--[@b23-co15_s1p058],[@b30-co15_s1p058]. Mechanical devices have also been shown to be effective.

2.5 Other Surgeries
-------------------

There is a paucity of research on the risk of [vte]{.smallcaps} and on its prevention in other surgical settings. Based on limited data and extrapolation from other surgical groups, unfractionated heparin and [lmwh]{.smallcaps} both appear relatively safe and effective, but solid evidence is lacking.

2.6 Mechanical Prophylaxis in Surgical Settings
-----------------------------------------------

As shown in one meta-analysis [@b31-co15_s1p058], compression stockings are effective in reducing the risk of [vte]{.smallcaps} by two thirds in patients at moderate risk. Pneumatic compression devices are also effective, but they are cumbersome and interfere with mobilization. Also, they are more likely than pharmacologic prophylaxis to fail in high-risk groups [@b32-co15_s1p058]. Compression devices are therefore currently reserved for situations in which anticoagulation is contraindicated. These devices are most effective when applied intraoperatively or immediately after surgery ([Table IV](#tIV-co15_s1p058){ref-type="table"})[@b33-co15_s1p058]--[@b35-co15_s1p058]. Whether mechanical methods in combination with anticoagulants result in additional risk reduction is not clear.

2.7 Summary: Surgical Settings
------------------------------

Good evidence supports the routine use of postoperative thromboprophylaxis in patients undergoing surgery for cancer ([Tables I](#tI-co15_s1p058){ref-type="table"} to [IV](#tIV-co15_s1p058){ref-type="table"}). That finding is endorsed by international and national consensus guidelines, including those from the American College of Chest Physicians ([accp]{.smallcaps})[@b9-co15_s1p058], the American Society of Clinical Oncology ([asco]{.smallcaps})[@b36-co15_s1p058], and the Italian Association of Medical Oncology ([aiom]{.smallcaps})[@b37-co15_s1p058]. Unfractionated heparin and [lmwh]{.smallcaps} are equally effective in preventing [vte]{.smallcaps} and have a comparable risk for bleeding. Less experience and data are available for fondaparinux. Extended prophylaxis should be strongly considered in patients with additional risk factors for [vte]{.smallcaps}. In those patients who have a contraindication for anticoagulation, mechanical methods are reasonable substitutes.

3. PRIMARY PREVENTION: MEDICAL SETTINGS
=======================================

3.1 Ambulatory Patients
-----------------------

The risk of symptomatic [vte]{.smallcaps} in the ambulatory outpatient setting is lower than that in the surgical setting, and little research had been done to investigate the role of anticoagulant prophylaxis. More recently, three separate randomized controlled trials have evaluated [lmwh]{.smallcaps} prophylaxis in patients with metastatic breast cancer, non-small-cell lung cancer, and grades and [iii]{.smallcaps} and [iv]{.smallcaps} malignant glioma ([Table V](#tV-co15_s1p058){ref-type="table"}) [@b38-co15_s1p058]--[@b40-co15_s1p058]. No significant difference in [vte]{.smallcaps} or major bleeding was observed between the groups receiving [lmwh]{.smallcaps} and placebo. Consequently, routine prophylaxis is not recommended in ambulatory patients. Notably, the risk of [vte]{.smallcaps} and major bleeding appear to vary considerably, depending on the type of tumour.

On the other hand, as many as 20%--30% of patients receiving thalidomide in combination with chemotherapy or high-dose corticosteroids for treatment of multiple myeloma will develop symptomatic [vte]{.smallcaps} [@b41-co15_s1p058],[@b42-co15_s1p058]. Although many studies have reported the use of warfarin, aspirin, or [lmwh]{.smallcaps}, insufficient reliable data are available to support the efficacy and safety of these agents. Whether lenalidomide is also associated with a high risk of [vte]{.smallcaps} is uncertain. Patients receiving vascular endothelial growth factor inhibitors such as bevacizumab also have an increased risk of arterial and, possibly, venous thrombosis [@b43-co15_s1p058],[@b44-co15_s1p058], but because of an increased bleeding tendency already associated with this treatment, anticoagulation prophylaxis is not recommended.

3.2 Hospitalized Patients
-------------------------

No study has been conducted in cancer patients to determine the effects of [vte]{.smallcaps} prophylaxis in the inpatient setting. Large randomized trials that included small numbers of cancer patients have shown that [lmwh]{.smallcaps} or fondaparinux can reduce the [vte]{.smallcaps} risk by 50% or more, but whether such results can apply to all hospitalized cancer patients is questionable, because of the higher risks for [vte]{.smallcaps} and major bleeding in those patients [@b45-co15_s1p058]--[@b47-co15_s1p058].

3.3 Summary: Medical Settings
-----------------------------

Based on limited data, routine prophylaxis in the outpatient setting is not recommended, but prophylaxis should be considered in patients receiving thalidomide- or lenalidomide-containing regimens. Anticoagulant prophylaxis for hospitalized patients is warranted based on studies in noncancer patients, but the risk--benefit ratio is uncertain, given the lack of randomized trial evidence.

4. PROPHYLAXIS FOR CENTRAL VENOUS CATHETERS
===========================================

Central venous catheters are frequently placed in cancer patients, and those devices represent an ongoing thrombogenic focus [@b48-co15_s1p058]. Many attempts have been made to reduce the incidence of thrombotic complications in this setting, but randomized placebo-controlled trials have failed to show a reduction in catheter-related thrombosis with thromboprophylaxis. In particular, low-dose warfarin [@b49-co15_s1p058], adjusted-dose warfarin [@b50-co15_s1p058], and prophylactic-dose [lmwh]{.smallcaps} [@b51-co15_s1p058],[@b52-co15_s1p058] do not reduce the 4% risk of symptomatic catheter--related thrombosis ([Table VI](#tVI-co15_s1p058){ref-type="table"}) [@b49-co15_s1p058]--[@b52-co15_s1p058]. For that reason and because of the possibility of increased risk of bleeding, the routine use of prophylaxis in this setting is not recommended [@b9-co15_s1p058].

5. SECONDARY PREVENTION
=======================

5.1 Treatment of VTE
--------------------

Traditional therapy for acute [vte]{.smallcaps} has consisted of initial therapy with unfractionated heparin or [lmwh]{.smallcaps}, followed by long-term warfarin therapy. Unfortunately, many cancer patients tolerate warfarin poorly, especially when receiving chemotherapy, with its ensuing gastrointestinal and hematologic side effects. Also, despite maintenance of therapeutic levels of warfarin, one third of patients experience recurrent [vte]{.smallcaps} or treatment-related bleeding [@b6-co15_s1p058],[@b7-co15_s1p058].

However, [lmwh]{.smallcaps} is clearly superior to warfarin with respect to convenience and efficacy. Given as a once-daily subcutaneous injection, [lmwh]{.smallcaps} does not require routine laboratory monitoring, has few drug interactions, and does not rely on gastrointestinal absorption. In the [clot]{.smallcaps} study, 676 cancer patients with acute [dvt]{.smallcaps} or pulmonary embolism were randomized to a 6-month course of traditional therapy with dalteparin followed by warfarin, or to dalteparin alone [@b53-co15_s1p058]. To reduce the risk of bleeding in the dalteparin-only group, the dalteparin dose was reduced by 20%--25% after the first month of therapy. After 6 months of treatment, the long-term dalteparin group experienced a 52% reduction in symptomatic recurrent [vte]{.smallcaps} (17% vs. 9%, *p* = 0.002) as compared with the group continuing on warfarin. In other words, 1 episode of recurrent [vte]{.smallcaps} was prevented for every 13 patients treated. Furthermore, the groups showed no significant difference in bleeding (4% vs. 6% respectively) and no difference in overall mortality.

Based on those results and on supportive findings from other trials ([Table VII](#tVII-co15_s1p058){ref-type="table"}) [@b53-co15_s1p058]--[@b56-co15_s1p058], the 2004 [accp]{.smallcaps} guidelines [@b57-co15_s1p058], the [asco vte]{.smallcaps} guidelines [@b36-co15_s1p058], and [aiom]{.smallcaps} [@b37-co15_s1p058] recommend the use of [lmwh]{.smallcaps} alone for treatment of [vte]{.smallcaps} in most patients with cancer. Currently, only dalteparin has received regulatory approval for long-term treatment of symptomatic [vte]{.smallcaps} in patients with cancer.

5.2 Recurrent VTE
-----------------

As mentioned earlier, recurrence of [vte]{.smallcaps} is more common in the setting of warfarin therapy than of [lmwh]{.smallcaps} therapy. Unfortunately, the optimal treatment for such patients has yet to be determined. Inferior caval filters have frequently been used in cases of warfarin failure, but evidence from a large randomized trial primarily in patients without cancer showed that, although the risk of short-term pulmonary embolism is reduced by about three quarters, patients receiving a filter are about twice as likely to develop recurrent [vte]{.smallcaps}. Also, no difference in overall survival was seen [@b58-co15_s1p058]. Furthermore, because of the increased risk of recurrent [vte]{.smallcaps}, cancer patients may be at higher risk for development of postphlebitic syndrome.

Based on the foregoing findings, using caval filters as treatment for recurrent [vte]{.smallcaps} cannot be recommended. Rather, changing a warfarin regimen to [lmwh]{.smallcaps}, or increasing the dose of [lmwh]{.smallcaps} would be appropriate.

5.3 Duration of Therapy
-----------------------

The optimum duration of anticoagulation in patients with cancer has not been investigated. Extrapolating from populations without cancer, most patients should receive a minimum of 3--6 months of therapy. However, given that cancer represents an ongoing risk factor in this population, the general recommendation is to continue anticoagulation for long as evidence of active malignancy continues. It is of foremost importance that patient care be tailored to suit the individual, with due consideration for quality of life and life expectancy.

5.4 Summary of Secondary Prevention
-----------------------------------

First-line treatment of [vte]{.smallcaps} in patients with cancer is [lmwh]{.smallcaps} for a minimum of 3--6 months. This approach is endorsed by the [accp]{.smallcaps}, [asco]{.smallcaps}, [aiom]{.smallcaps}, and the National Comprehensive Cancer Network. The optimum duration is not known, but treatment is usually continued for as long as evidence of malignancy continues.

6. FUTURE DIRECTIONS
====================

The [lmwh]{.smallcaps}s have simplified and improved the prevention and treatment of [vte]{.smallcaps} in patients with cancer. Much work must still be done to help identify high-risk patients who would benefit from primary thromboprophylaxis for extended periods after cancer surgery, during medical hospitalization, for prevention of catheter-related thrombosis, and for prevention of [vte]{.smallcaps} associated with highly thrombogenic agents (thalidomide, for example). Also, optimal management in patients with established [vte]{.smallcaps} should be investigated, especially with regard to duration of therapy and the potential role, if any, of invasive strategies such as filter insertion. Lastly, education of physicians to improve the appropriate utilization of prophylaxis in various settings will go a long way toward reducing morbidity and mortality in this vulnerable population.

7. SUMMARY
==========

Recommendations for managing risk of thrombotic events:

-   Cancer patients undergoing surgery require [vte]{.smallcaps} prophylaxis, and this prophylaxis can safely be extended in high-risk patients after discharge.

-   Medical inpatients with cancer should receive [vte]{.smallcaps} prophylaxis unless absolute contraindications---active bleeding, for instance---are present.

-   Prophylaxis for central venous catheters is not recommended.

-   Prophylaxis in ambulatory patients is not recommended, except in those who are receiving thalidomide- or lenalidomide-based combination chemotherapy.

-   Venous thromboembolism is best treated with [lmwh]{.smallcaps} for a minimum of 3--6 months, and treatment can be continued for as long as active cancer is present.

-   Inferior caval filters prevent pulmonary embolism in the short term, but they carry a long-term risk of increased [vte]{.smallcaps} and should therefore be avoided when anticoagulation can be administered.

###### 

Randomized controlled trials for primary prophylaxis in cancer-related major abdominal and pelvic surgery

  Trial                                           Surgical setting       Cancer patients (*n*)   Regimen                     Duration of treatment                     Outcome                                    Incidences                                                                                                                                                                                              
  ----------------------------------------------- ---------------------- ----------------------- --------------------------- ----------------------------------------- ------------------------------------------ ------------------------------------------------------------------------------ ------ ------ -------- ------------------------------------------------ ------------------------------------------------ ---------------------------------------------------
  Enoxacan Study Group, 1997 [@b10-co15_s1p058]   Abdominal and pelvic   631                     Enoxapari 40 mg daily       [ufh]{.smallcaps} 5000 IU 3 times daily   10 Days                                    [vte]{.smallcaps} on bilateral venography or pulmonary scintigraphy            14.7   18.2   \>0.05   4.1                                              2.9                                              \>0.05
  McLeod *et al.*, 2001 [@b11-co15_s1p058]        Colorectal             324                     Enoxaparin 40 mg daily      [ufh]{.smallcaps} 5000 IU 3 times daily   Up to 10 days                              [pe]{.smallcaps}, venographic [dvt]{.smallcaps} at postoperative days 5, 9     13.9   16.9   0.052    2.7[a](#tfn1-co15_s1p058){ref-type="table-fn"}   1.5[a](#tfn1-co15_s1p058){ref-type="table-fn"}   0.136[a](#tfn1-co15_s1p058){ref-type="table-fn"}
  Agnelli *et al.*, 2005 [@b12-co15_s1p058]       Major abdominal        1941                    Fondaparinux 2.5 mg daily   Dalteparin 5000 IU daily                  5--9 Days                                  Venographic [dvt]{.smallcaps} or [pe]{.smallcaps} up to postoperative day 10   4.7    7.7    \<0.05   3.4                                              2.5                                              0.355
  Bergqvist *et al.*, 2002 [@b13-co15_s1p058]     Abdominal and pelvic   332                     Enoxaparin 40 mg daily      Enoxaparin 40 mg daily                    27--31 Days (study) 6--10 Days (control)   Bilateral venography between days 25 and 31                                    4.8    12.0   0.02     0.4                                              0                                                \>0.99
  Rasmussen *et al.*, 2006 [@b14-co15_s1p058]     Major abdominal        198                     Dalteparin 5000 IU daily    Dalteparin 5000 IU daily                  28 Days (study) 7 Days (control)           Venographic [vte]{.smallcaps} on postoperative days 7--28                      8.8    19.6   0.03     0.5[a](#tfn1-co15_s1p058){ref-type="table-fn"}   1.8[a](#tfn1-co15_s1p058){ref-type="table-fn"}   \>0.05[a](#tfn1-co15_s1p058){ref-type="table-fn"}

Results for the overall study population, including cancer and noncancer patients.

[vte]{.smallcaps} = venous thromboembolism; [ufh]{.smallcaps} = unfractionated heparin; [pe]{.smallcaps} = pulmonary embolism; [dvt]{.smallcaps} = deep vein thrombosis.

###### 

Randomized controlled trials for primary prophylaxis in cancer-related neurosurgery

  Trial                                          Surgical setting                                    Patients (*n*)   Regimen                                                              Duration of treatment                                                               Outcome                                Incidences                                                                                                
  ---------------------------------------------- --------------------------------------------------- ---------------- -------------------------------------------------------------------- ----------------------------------------------------------------------------------- -------------------------------------- -------------------------------------------------------------------- ------ ------ -------- ------ ------ --------
  Nurmohamed *et al.*, 1996 [@b15-co15_s1p058]   Craniotomy or spinal surgery for tumour or injury   485              Nadroparin 7500 IU daily and [gcs]{.smallcaps}                       Placebo and [gcs]{.smallcaps}                                                       10 Days or until discharge             Venographic [dvt]{.smallcaps} at day 10                              18.7   26.3   0.047    2.50   0.80   0.87
  Agnelli *et al.*, 1998 [@b16-co15_s1p058]      Elective cranial or spinal surgery for tumours      307              Enoxaparin 40 mg daily and [gcs]{.smallcaps}                         Placebo and [gcs]{.smallcaps}                                                       At least 7 days                        Venographic [dvt]{.smallcaps} at day 8, or [pe]{.smallcaps}          17     33     0.004    3      3      \>0.05
  Goldhaber *et al.*, 2002 [@b17-co15_s1p058]    Craniotomy for brain tumour                         150              Enoxaparin 40 mg daily and [gcs]{.smallcaps} and [ipc]{.smallcaps}   [ufh]{.smallcaps} 5000 IU twice daily and [gcs]{.smallcaps} and [ipc]{.smallcaps}   Until [vte]{.smallcaps} or discharge   Ultrasonographic [dvt]{.smallcaps} at discharge                      12     6.7    0.401    2.7    1.3    \>0.05
  Macdonald *et al.*, 2003 [@b18-co15_s1p058]    Craniotomy                                          100              Dalteparin 2500 IU daily and [ipc]{.smallcaps}                       [ufh]{.smallcaps} 5000 IU twice daily and [ipc]{.smallcaps}                         7 Days, or until ambulating            [pe]{.smallcaps}, or ultrasonographic [dvt]{.smallcaps} at 1 month   4      0      \>0.05   4      2      \>0.05

[vte]{.smallcaps} = venous thromboembolism; [gcs]{.smallcaps} = graduated compression stockings; [dvt]{.smallcaps} = deep vein thrombosis; [pe]{.smallcaps} = pulmonary embolism; [ipc]{.smallcaps} = intermittent pneumatic compression; [ufh]{.smallcaps} = unfractionated heparin.

###### 

Randomized controlled trials for primary prophylaxis in cancer-related gynecologic surgery

  Trial                                               Patients (*n*)   Regimen                                                                         Duration of treatment                                                  Outcome           Incidences                                                                                                                                                                                                                                                 
  --------------------------------------------------- ---------------- ------------------------------------------------------------------------------- ---------------------------------------------------------------------- ----------------- ------------------------------------------------------------------------------------------------------------- ----- ------ -------- ------ --------------------------------------------------------------------------------------------------------------- --------
  Heilmann *et al.*, 1989 [@b19-co15_s1p058]          300              [lmwh]{.smallcaps} 1500 IU daily                                                [ufh]{.smallcaps} 5000 IU 3 times daily                                7 Days            [pe]{.smallcaps}, [dvt]{.smallcaps} by impedance plethysmography to day 7                                     1.3   4.0    \>0.05          No significant difference in clinical and laboratory measures, specific incidence of major bleeding not cited   
  Clarke--Pearson *et al.*, 1990 [@b20-co15_s1p058]   200              [ufh]{.smallcaps} 5000 IU every 8 hours pre- and postoperatively                No prophylaxis                                                         Until discharge   [pe]{.smallcaps}, [dvt]{.smallcaps} by ^125^I-labelled fibrinogen scan, impedance plethysmography to day 30   6.2   18.4   0.008           No significant difference in clinical and laboratory measures, specific incidence of major bleeding not cited   
  Fricker *et al.*, 1988 [@b21-co15_s1p058]           80               Dalteparin 2500 IU 2 hours preoperatively and at 12 hours, then 5000 IU daily   [ufh]{.smallcaps} 5000 IU 2 hours preoperatively, then 3 times daily   10 Days           [pe]{.smallcaps}, [dvt]{.smallcaps} by ^125^I-labelled fibrinogen scan, venography to 4 weeks                 0     2.5    \>0.05   5.1    2.5                                                                                                             \>0.05
  Von Tempelhoff *et al.*, 1997 [@b22-co15_s1p058]    60               [lmwh]{.smallcaps} 3000 IU daily                                                [ufh]{.smallcaps} 5000 IU 3 times daily                                7 Days            [pe]{.smallcaps} on scintigraphy, by impedance [dvt]{.smallcaps} plethysmography, venography, up to day 30    6.7   0      \>0.05          Not assessed                                                                                                    
  Heilmann *et al.*, 1998 [@b23-co15_s1p058]          324              Certoparin 3000 IU daily                                                        [ufh]{.smallcaps} 5000 IU 3 times daily                                7 Days            [dvt]{.smallcaps} by impedance plethysmography, venography up to day 10                                       6.3   6.1    1.0      16.8   28.7                                                                                                            0.01

[vte]{.smallcaps} = venous thromboembolism; [lmwh]{.smallcaps} = low molecular weight heparin; [ufh]{.smallcaps} = unfractionated heparin; [pe]{.smallcaps} = pulmonary embolism; [dvt]{.smallcaps} = deep vein thrombosis.

###### 

Randomized controlled trials for primary prophylaxis using pneumatic compression stockings

  Trial                                               Surgical setting         Patients(*n*)   Regimen                                                            Duration of treatment                        Outcome                                                                                                                       Incidence of [vte]{.smallcaps}                                                                                                                                 
  --------------------------------------------------- ------------------------ --------------- ------------------------------------------------------------------ -------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ ------ ------ ---------
  Clarke--Pearson *et al.*, 1993 [@b33-co15_s1p058]   Gynecologic malignancy   208             [ufh]{.smallcaps} 5000 IU 3 times daily pre- and postoperatively   Intra- and postoperative [ipc]{.smallcaps}   [ufh]{.smallcaps}: 7 days postoperatively, or until discharge [ipc]{.smallcaps}: 5 days postoperatively, or until discharge   [dvt]{.smallcaps} by ^125^I-labelled fibrinogen scan, impedance plethysmography; [pe]{.smallcaps} on scintigraphy up to day 30 postoperatively   6.5    4.0    0.54
  Clarke--Pearson *et al.*, 1984 [@b34-co15_s1p058]   Gynecologic malignancy   194             Intra- and postoperative [ipc]{.smallcaps}                         No prophylaxis                               Maximum 24 hours postoperatively                                                                                              [dvt]{.smallcaps} by ^125^I-labelled fibrinogen scan, impedance plethysmography                                                                  18.6   12.4   \>0.05
  Clarke--Pearson *et al.*, 1984 [@b35-co15_s1p058]   Gynecologic malignancy   107             Intra- and postoperative [ipc]{.smallcaps}                         No prophylaxis                               5 Days                                                                                                                        [dvt]{.smallcaps} by ^125^I-labelled fibrinogen scan, impedance plethysmography                                                                  12.7   34.6   \<0.005

[vte]{.smallcaps} = venous thromboembolism; [ufh]{.smallcaps} = unfractionated heparin; [ipc]{.smallcaps} = intermittent pneumatic compression; [dvt]{.smallcaps} = deep vein thrombosis; [pe]{.smallcaps} = pulmonary embolism.

###### 

Randomized controlled trials for primary prophylaxis in medical outpatients with cancer

  Trial                                      Medical setting                                      Patients(*n*)   Regimen                                                                         Duration of treatment   Outcome                                   Incidences                                                                           
  ------------------------------------------ ---------------------------------------------------- --------------- ------------------------------------------------------------------------------- ----------------------- ----------------------------------------- ------------------------------------------------- ----- ----- -------- ------ ------ --------
  Levine *et al.*, 1994 [@b38-co15_s1p058]   Breast cancer stage [iv]{.smallcaps}                 311             Warfarin 1 mg daily for 6 weeks, then adjusted for [inr]{.smallcaps} 1.3--1.9   Placebo                 1 Week after completion of chemotherapy   Symptomatic [vte]{.smallcaps}                     0.7   4.4   0.031    5.30   3.10   0.4
  Haas *et al.*, 2005 [@b39-co15_s1p058]     Advanced breast cancer                               353             Certoparin 3000 IU daily                                                        Placebo                 6 Months                                  Ultrasonographic [dvt]{.smallcaps}                4.0   3.9   \>0.05   1.7    0      \>0.05
                                             Advanced non-small-cell lung cancer                  547             Certoparin 3000 IU daily                                                        Placebo                 6 Months                                  Ultrasonographic [dvt]{.smallcaps}                4.5   8.3   0.07     3.7    2.2    \>0.05
  Perry *et al.*, 2007 [@b40-co15_s1p058]    Glioma grade [iii]{.smallcaps} or [iv]{.smallcaps}   186             Dalteparin 5000 IU daily                                                        Placebo                 6 Months                                  [pe]{.smallcaps}, symptomatic [dvt]{.smallcaps}   11    17    0.3      5.1    1.2    0.2

[vte]{.smallcaps} = venous thromboembolism; [dvt]{.smallcaps} = deep vein thrombosis; [pe]{.smallcaps} = pulmonary embolism; [inr]{.smallcaps} = international normalized ratio.

###### 

Randomized controlled trials for primary prophylaxis in central venous catheters in cancer patients

  Trial                                        Patients (*n*)   Regimen                                                             Duration of treatment   Outcome                                          Incidences                                                                                                 
  -------------------------------------------- ---------------- ------------------------------------------------------------------- ----------------------- ------------------------------------------------ --------------------------------------------------------------------- ------ ------ -------- ------- ----- --------
  Couban *et al.*, 2005 [@b49-co15_s1p058]     255              Warfarin 1 mg                                                       Placebo                 Until [dvt]{.smallcaps}, or until line removed   [cvc]{.smallcaps}-associated thrombosis on ultrasound or venography   4.6    4.0    \>0.05   0       2     0.5
  Young *et al.*, 2005 [@b50-co15_s1p058]      1589             Adjusted warfarin for [inr]{.smallcaps} 1.5--2.0 or warfarin 1 mg   Placebo                 Until [dvt]{.smallcaps}, or until line removed   [cvc]{.smallcaps}-associated thrombosis on ultrasound or venography   5      6      0.84     2       0.2   0.07
  Verso *et al.*, 2005 [@b51-co15_s1p058]      321              Enoxaparin 40 mg daily                                              Placebo                 Until [dvt]{.smallcaps}, or until line removed   Venographic [dvt]{.smallcaps}, or [pe]{.smallcaps}                    14.1   18.0   0.35     0       0     \>0.05
  Karthaus *et al.*, 2006 [@b52-co15_s1p058]   425              Dalteparin 5000 IU daily                                            Placebo                 12 Weeks                                         [pe]{.smallcaps}, venographic or ultrasonographic [dvt]{.smallcaps}   3.7    3.4    0.88     0.004   0     \>0.05

[vte]{.smallcaps} = venous thromboembolism; [dvt]{.smallcaps} = deep vein thrombosis; [cvc]{.smallcaps} = central venous catheter; [inr]{.smallcaps} = international normalized ratio; [pe]{.smallcaps} = pulmonary embolism.

###### 

Randomized controlled trials for treatment of cancer-related venous thromboembolism ([vte]{.smallcaps})

  Trial                                        Patients (*n*)   Regimen                                                                     Duration of treatment                                                               Outcome                                Incidences                                                                                                                                                                                                                                       
  -------------------------------------------- ---------------- --------------------------------------------------------------------------- ----------------------------------------------------------------------------------- -------------------------------------- ----------------------------------------------------- ------------------------------------------------- ------------------------------------------------- --------------------------------------------------- --------------------------- ------ --------
  Meyer *et al.*, 2002 [@b54-co15_s1p058]      146              Enoxaparin 1.5 mg/kg daily                                                  Enoxaparin 1.5 mg/kg daily for 5--7 days, then warfarin at [inr]{.smallcaps} 2--3   3 Months                               Combined recurrent [vte]{.smallcaps} and hemorrhage   10.5[a](#tfn8-co15_s1p058){ref-type="table-fn"}   21.1[a](#tfn8-co15_s1p058){ref-type="table-fn"}   0.09[a](#tfn8-co15_s1p058){ref-type="table-fn"}     7.0                         16.0   0.09
  Lee *et al.*, 2003 [@b53-co15_s1p058]        672              Dalteparin 200 IU/kg daily for 1 month, then 150 IU/kg daily for 5 months   Dalteparin 200 IU/kg daily for 5--7 days, then warfarin at [inr]{.smallcaps} 2--3   As described in "Regimen"              Recurrent [vte]{.smallcaps}                           9.0                                               17.0                                              0.002                                               6                           4      0.27
  Deitcher *et al.*, 2006 [@b55-co15_s1p058]   122              Enoxaparin 1 mg/kg twice daily, then 1.0 mg/kg daily or 1.5 mg/kg daily     Enoxaparin 1 mg/kg twice daily, then warfarin at [inr]{.smallcaps} 2--3             5 Days at twice daily, then 6 months   Recurrent [vte]{.smallcaps}                           6.9 (1 mg), 6.3 (1.5 mg)                          10.00                                             \>0.05                                              6.5 (1 mg), 11.1 (1.5 mg)   2.90   \>0.05
  Hull *et al.*, 2006 [@b56-co15_s1p058]       200              Tinzaparin 175 IU/kg daily                                                  [ufh]{.smallcaps} infusion then warfarin at [inr]{.smallcaps} 2--3                  3 Months                               Recurrent [vte]{.smallcaps}                           6.0[b](#tfn9-co15_s1p058){ref-type="table-fn"}    10.0[b](#tfn9-co15_s1p058){ref-type="table-fn"}   \>0.05[b](#tfn9-co15_s1p058){ref-type="table-fn"}   7.0                         7.0    \>0.05

Combined 3-month incidence of patients with either recurrent venous thromboembolism or major bleeding.

3-Month incidence of patients with recurrent venous thromboembolism.

[vte]{.smallcaps} = venous thromboembolism; [inr]{.smallcaps} = international normalized ratio.
